# TUXEDO-3 (NCT05865990)

> HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05865990
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: MedSIR
- Conditions: Metastatic Breast Cancer; Advanced Non-Small Cell Squamous Lung Cancer; Solid Tumor, Adult
- Interventions: Patritumab deruxtecan
- Enrollment: 63
- Primary outcome: Efficacy: Local determination of intracranial objective response rate (ORR-IC) in cohort 1 and cohort 2.
- Primary outcome: Efficacy: Overall survival (OS) rate at 3 months in cohort 3.

## Commentary we found

- YouTube: 10
- X threads: 9
- Podcasts: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=tuxedo-3-nct05865990

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05865990", "email": "<work email>"}; the inbox owner confirms by the emailed link.